A 2021 survey of American high school students found that of those who were sexually active and engaging in sex with opposite-sex partners, 20.9 percent were using the birth control pill to prevent pregnancy. Prevalence was highest among white students, at 25.1 percent.

As of 2022, Czechia had the highest share in Europe of women aged 15 to 49 years using the birth control pill, with over 54 percent using this form of contraception. Additionally, Netherlands had a high level of contraceptive pill use at 49 percent. In the Balkans there is low usage of the birth control pill with less than two percent of women using the pill in Albania, Bosnia-Herzegovina, Montenegro, and North Macedonia.

In the United States, around 28 percent of sexually active students in the U.S. in twelfth grade reported using birth control pills as their primary contraceptive method. This statistic depicts the percentage of high school students using birth control pills as contraception during their last sexual intercourse in the U.S. in 2019, by grade.

The global hormonal contraceptive market is a substantial and rapidly growing sector, projected to experience significant expansion over the forecast period (2025-2033). While precise figures for market size and CAGR aren't provided, leveraging industry reports and considering the diverse range of products (oral contraceptives, injectables, implants, patches, rings), a conservative estimate places the 2025 market size at approximately $20 billion USD, with a CAGR of around 5% projected through 2033. This growth is fueled by several key drivers. Increased awareness of family planning and reproductive health, coupled with rising female participation in the workforce and changing societal norms around contraception, significantly impact market demand. Moreover, advancements in contraceptive technology, leading to more convenient and effective options like long-acting reversible contraceptives (LARCs) such as implants and IUDs (although not explicitly mentioned as hormonal, they are often included in broader contraceptive markets), are driving market expansion. Government initiatives promoting reproductive healthcare access in developing nations also contribute to the overall growth. However, the market faces certain restraints. These include concerns surrounding potential side effects associated with hormonal contraceptives, varying levels of access to healthcare and education about contraceptive options across different regions, and religious or cultural beliefs that restrict the use of contraceptives. Market segmentation reveals substantial variations across application (hospitals, clinics, household use) and product types. Oral contraceptive pills maintain a significant market share due to established familiarity and widespread availability, but the demand for long-acting reversible contraceptives (LARCs) is expected to grow faster, due to their convenience and effectiveness. Geographically, North America and Europe currently dominate the market, owing to higher per capita healthcare expenditure and greater access to modern contraceptives. However, emerging markets in Asia-Pacific and Africa are poised for substantial growth, driven by rising disposable incomes and improved healthcare infrastructure. Competitive dynamics among major pharmaceutical companies, including those listed, are intense, driving innovation and price competition within the market.

A survey of college students in the United States from the fall of 2023 found that the most common method of birth control among college students is the male condom, followed by birth control pills, and the withdrawal method. At that time, about half of college students in the U.S. reported they used a male condom to prevent pregnancy the last time they had vaginal intercourse, while 39 percent used birth control pills.

Contraception among women in the United States Similarly to college students, male condoms and oral contraceptives are the most common forms of contraception among all adult women in the United States. As of 2022, around 32 percent of women of reproductive age in the United States had used male condoms in the past year, while 33 percent had used oral contraceptives. These forms of contraception are more common among women aged 18 to 25 years, while the intrauterine device (IUD) is more common among women aged 26 to 35 years than any other age group. The number one reason U.S. women use contraception is to avoid pregnancy.

Contraceptive use among high school students In 2019, around 49 percent of male and 39 percent of female high school students stated condoms were their primary contraceptive method. This was the most popular form of contraception among high school students, followed by birth control pills. Around 28 percent of high school students in grade 12 stated they used birth control pills as their primary method of birth control the last time they had sexual intercourse, compared to 26 percent of those in 11th grade, and 18 percent of 10th graders.

Snapshot img

Hormonal Contraceptives Market Size 2024-2028

The hormonal contraceptives market size is forecast to increase by USD 4.35 billion at a CAGR of 4.2% between 2023 and 2028.

The market is driven by several factors, including the rising number of unplanned pregnancies and the significance of family planning, particularly in developing countries. The endocrine system plays a crucial role in the effectiveness of hormonal contraceptives, which prevent ovulation through the use of synthetic hormones like progesterone and estrogen in combination or progestin-only. Hormonal contraceptives offer benefits beyond birth control, such as HIV protection and regulation of menstrual cycles. Organizations and healthcare providers continue to promote awareness and education about the various contraceptive methods available to women, enabling them to make informed decisions about their reproductive health.
However, challenges such as lack of reimbursement and potential side effects can hinder market growth. The importance of women's health and advancements in hormonal contraceptive research continue to shape the market landscape. This analysis report provides an in-depth examination of the market trends, growth drivers, and challenges in the market. OTC contraceptives, such as emergency contraceptive pills and certain types of oral contraceptive pills, offer convenience and confidentiality for women who prefer not to obtain a prescription from a healthcare provider.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Hormonal contraceptives are a type of birth control methods that utilize synthetic hormones, specifically progestin and estrogen, to prevent pregnancy. These hormones work by preventing ovulation, thickening cervical mucus to hinder sperm from reaching the fertilized eggs, and thinning the lining of the uterus to prevent implantation. The endocrine system plays a crucial role in the functioning of hormonal contraceptives. Progestin-only contraceptives and combination hormonal contraceptives, which include oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, patches, progestogen injectables, intrauterine devices (IUDs), implants, and over-the-counter (OTC) contraceptives, are the primary types of hormonal contraceptives available in the market.
Moreover, the hormonal contraceptive market has witnessed significant growth due to the effectiveness of these methods in preventing unintended pregnancies. According to the Centers for Disease Control and Prevention (CDC), more than 14 million women in the United States use hormonal contraceptives. The primary mechanism of hormonal contraceptives is to prevent fertilization by preventing ovulation or preventing the fertilized egg from implanting in the uterus. Progestin-only contraceptives are effective in preventing ovulation, while combination hormonal contraceptives prevent both ovulation and thicken cervical mucus. Hormonal contraceptives offer additional benefits, including protection against certain types of cancers, such as ovarian and endometrial cancer, and relief from menstrual cramps and heavy periods.
Similarly, some hormonal contraceptives, such as certain types of IUDs, also offer protection against HIV and other sexually transmitted infections (STIs). Long-acting contraceptives, such as IUDs and implants, have gained popularity due to their effectiveness and convenience. These methods provide continuous hormonal contraception for several years, requiring minimal user intervention. The hormonal contraceptive market is expected to continue growing due to the increasing awareness of family planning and the availability of various types of hormonal contraceptives to cater to diverse needs and preferences.
The market is also driven by the development of new and innovative hormonal contraceptive products, such as extended-cycle pills and continuous-use IUDs. In conclusion, hormonal contraceptives are an essential component of family planning and have proven to be effective in preventing unintended pregnancies. The hormonal contraceptive market is diverse and offers various types of methods to cater to the unique needs and preferences of women. The continued growth of the market is driven by the development of new and innovative products, increasing awareness of family planning, and the convenience and effectiveness of hormonal contraceptives.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Method

  Oral contraceptives
  Implanted contraceptives
  Injected contraceptives
  Intrauterine
  Others


Geography

  North America

    Canada
    Mexico
    US


  Asia

    Chi

In 2022, mood changes and weight gain were the most common side effects from contraception experienced by women in the U.S. in the past year, as reported by almost half of respondents. In addition, nearly eight out of ten women who used contraception said they had experienced two or more side effects. This statistic illustrates the percentage of contraceptive-using women in the U.S. who experienced select side effects from contraception that were unexpected or more severe than expected as of 2022.

The global market for female oral contraceptives is a significant and dynamic sector within the pharmaceutical industry. While precise market size figures are unavailable, considering the established presence of major players like Bayer, Janssen, and Pfizer, coupled with a consistent demand driven by family planning needs, a reasonable estimate for the 2025 market size could be in the range of $8-10 billion USD. This market demonstrates a steady Compound Annual Growth Rate (CAGR), which we can conservatively estimate to be between 3-5% for the forecast period (2025-2033). Key drivers include increasing awareness of family planning options, rising female participation in the workforce, and advancements in contraceptive technology leading to safer and more effective options. Emerging trends include a growing preference for extended-cycle and low-dose formulations, as well as increasing demand for personalized contraceptive counseling and access. However, market restraints include concerns surrounding potential side effects, varying levels of access and affordability across different geographical regions, and regulatory hurdles related to product approval and distribution. Segmentation within the market involves different types of oral contraceptives (combined oral contraceptives, progestin-only pills), dosage forms, and distribution channels. Leading companies such as Bayer, Janssen, Teva, and Pfizer, hold substantial market share, driven by strong brand recognition and extensive distribution networks. Regional variations exist, with developed markets exhibiting higher per capita consumption compared to emerging economies. Sustained growth will likely depend on overcoming accessibility barriers, expanding awareness campaigns focused on safety and efficacy, and developing innovative formulations that address unmet needs, such as extended-cycle options with minimal side effects. The market is expected to maintain its steady growth trajectory, propelled by persistent demand and ongoing technological advancements.

Central African Republic CF: Contraceptive Prevalence: Any Methods: % of Women Aged 15-49 data was reported at 17.800 % in 2019. This records an increase from the previous number of 15.180 % for 2010. Central African Republic CF: Contraceptive Prevalence: Any Methods: % of Women Aged 15-49 data is updated yearly, averaging 17.800 % from Dec 1995 (Median) to 2019, with 5 observations. The data reached an all-time high of 27.943 % in 2000 and a record low of 14.800 % in 1995. Central African Republic CF: Contraceptive Prevalence: Any Methods: % of Women Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Central African Republic – Table CF.World Bank.WDI: Social: Health Statistics. Contraceptive prevalence, any method is the percentage of married women ages 15-49 who are practicing, or whose sexual partners are practicing, any method of contraception (modern or traditional). Modern methods of contraception include female and male sterilization, oral hormonal pills, the intra-uterine device (IUD), the male condom, injectables, the implant (including Norplant), vaginal barrier methods, the female condom and emergency contraception. Traditional methods of contraception include rhythm (e.g., fertility awareness based methods, periodic abstinence), withdrawal and other traditional methods.;Household surveys, including Demographic and Health Surveys and Multiple Indicator Cluster Surveys. Largely compiled by United Nations Population Division (World Contraceptive Use 2024).;Weighted average;

The market for long-acting and short-acting oral contraceptives is a dynamic sector characterized by significant growth and evolving consumer preferences. Let's assume a 2025 market size of $15 billion USD, reflecting the substantial global demand for birth control options. A Compound Annual Growth Rate (CAGR) of 5% over the forecast period (2025-2033) is reasonable, considering factors such as increasing awareness of reproductive health, expanding access to healthcare, and the ongoing development of innovative contraceptive technologies. Key drivers include rising female participation in the workforce, greater emphasis on family planning, and increased government initiatives promoting reproductive health services. Trends indicate a shift towards long-acting reversible contraceptives (LARCs) like intrauterine devices (IUDs) and implants, driven by their high efficacy and reduced user burden compared to daily oral pills. However, challenges remain, including misconceptions about contraceptive safety and effectiveness, varying access to healthcare across different regions, and the cost of LARCs which can be a barrier for some populations. Market segmentation is crucial; differentiating between short-acting oral contraceptives (the pill) and LARCs, and further segmenting by product type (e.g., combined vs. progestin-only pills, different IUD types) will provide a comprehensive market view. The competitive landscape is likely populated by both large pharmaceutical companies and specialized reproductive healthcare providers. Analyzing market data across major geographical regions (North America, Europe, Asia-Pacific, etc.) will reveal significant regional variations in market size, growth rates, and the adoption of different contraceptive methods. The forecast for 2025-2033 suggests continuous growth, with the market expected to expand considerably by 2033, reaching approximately $23 billion USD (based on a 5% CAGR). This growth trajectory is underpinned by several factors. Firstly, the ongoing research and development of new and improved contraceptive formulations (e.g., extended-cycle pills, improved hormonal profiles) promises to further enhance market appeal. Secondly, educational campaigns aimed at addressing misinformation and promoting responsible family planning will contribute to market expansion. Thirdly, increased affordability and accessibility of contraceptives, especially in developing nations, will play a significant role. Despite the projected positive growth, regulatory hurdles, evolving societal attitudes towards contraception, and potential fluctuations in healthcare spending could influence future market trends. Detailed competitive analysis, incorporating factors like pricing strategies, brand awareness, and technological advancements will help in strategic decision-making within this market.

ABSTRACT Objective: To verify the association between Social Determinants of Health and birth control methods used by women of childbearing age. Methods: Documentary and retrospective study, performed at a Brazilian Natural Birth Center with evaluation of the medical records of patients seen between 2003 and 2011 (n=2410). Data were collected on identification and general history, gynecological, sexual and obstetric. Results: Hormone birth control methods were the most used among participants (25.0%); followed by barrier methods (21.5%) and surgical methods (19.3%). Statistical associations were observed regarding age, menarche, onset of sexual activity, pregnancy, miscarriage, smoking, hypertension, marital status, gynecological care and schooling with the choice of methods. Conclusion: The results confirm the importance of studies involving Social Determinants of Health, since they interfere in the way women choose birth control methods and the risks that this choice may pose to their health.

Snapshot img

Emergency Contraceptive Pills Market Size 2025-2029

The emergency contraceptive pills market size is forecast to increase by USD 258.4 million, at a CAGR of 4.5% between 2024 and 2029.

The Emergency Contraceptive Pills (ECP) market is driven by a rising number of initiatives to create awareness about family planning and the importance of preventing unintended pregnancies. This trend is particularly significant in regions where access to regular contraceptive methods may be limited or ineffective. However, market growth is challenged by local governments limiting access to ECPs due to cultural, religious, or political reasons. These restrictions can hinder market expansion and limit the reach of these essential health products to those who need them most.
Companies operating in the ECP market must navigate these regulatory complexities while continuing to invest in awareness campaigns and product innovation to meet the evolving needs of consumers. Effective strategies will include collaborating with local organizations, advocacy groups, and healthcare providers to expand access and ensure affordability, ultimately contributing to improved reproductive health outcomes and gender equality.

What will be the Size of the Emergency Contraceptive Pills Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, influenced by various factors in the global health sector. Distribution channels expand as online pharmacies and retail outlets increase accessibility. Health Insurance coverage remains a critical consideration, with ongoing negotiations impacting patient access. Drug interactions and adverse effects necessitate continual safety studies and regulatory approval. Marketing and promotion strategies adapt to reach diverse demographics, including public health initiatives and sexual health education. Reproductive health remains a priority, with contraceptive counseling and patient education integral to effective use. Clinical trials explore new dosage forms and mechanisms, such as implantation prevention and ovulation inhibition. Access to healthcare is a continual focus, with efforts to expand availability and reduce barriers.

Drug development advances with the introduction of generic drugs and alternative contraceptive options, such as the copper IUD. FDA approval processes and prescription requirements ensure safety and efficacy. Social media marketing and patient education campaigns raise awareness and promote safe sex practices. Ongoing research addresses unintended pregnancy prevention and HIV prevention. Pricing strategies and over-the-counter availability continue to shape market dynamics. Healthcare providers play a crucial role in emergency contraception, offering counseling and administering medications. Pharmaceutical manufacturing and regulatory bodies work to ensure quality and safety. Oral administration remains the primary method, but new technologies and dosage forms are under investigation.

Emergency contraception effectiveness is a continuous area of study, with ongoing efficacy and safety studies. Adverse effects and side effects are closely monitored, with efforts to minimize risks. The market's evolution reflects the ongoing commitment to women's health and reproductive rights.

How is this Emergency Contraceptive Pills Industry segmented?

The emergency contraceptive pills industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Distribution Channel

  Retail stores
  Online stores


Type

  Combination pills
  Progesterone pills


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

.

By Distribution Channel Insights

The retail stores segment is estimated to witness significant growth during the forecast period.

In the realm of healthcare, the market for emergency contraceptive pills (ECPs) continues to evolve, with various entities shaping its dynamics. Retail stores, including supermarkets, hypermarkets, departmental stores, pharmacies and clinics, and other retail outlets, serve as significant distribution channels for these medications. Brands like Plan B One-Step by Foundation Consumer Healthcare are available at retailers such as Walmart, Walgreens, and CVS Pharmacy. Retailers focus on enhancing the consumer experience in purchasing ECPs by ensuring knowledgeable sales staff, inspiring trust and confidence in the buying process. This trend benefits the global market for emergency contraceptive pills. The rise in

Birth Control Products Market Outlook

The global birth control products market size is projected to witness remarkable growth, reaching an estimated value of $XX billion by 2032 from $XX billion in 2023, with a compound annual growth rate (CAGR) of X%. This significant expansion is primarily driven by increasing awareness about reproductive health and family planning, coupled with the rising population and the need to curb unintended pregnancies. The market is also stimulated by technological advancements in contraceptive methods and the growing acceptance of birth control products across different demographic segments. Additionally, supportive government initiatives and policies are playing a crucial role in promoting the use of contraceptives, further propelling the market forward.

The growth of the birth control products market is significantly influenced by the rising awareness and education regarding reproductive health and family planning. Governments and non-profit organizations across the globe are investing heavily in initiatives that educate individuals, particularly women, about the benefits and availability of various contraceptive methods. Campaigns and educational programs aim to disseminate critical information that empowers individuals to make informed choices regarding their reproductive health. This increase in awareness has led to a greater acceptance and adoption rate of birth control products, especially in regions where there was previously limited access or cultural resistance to contraceptive methods. As a result, the market is experiencing a surge in demand, with more people opting for different forms of contraception to suit their specific needs.

Another key growth factor driving the market is the technological advancements in contraceptive methods, which are making birth control more effective, convenient, and accessible. Continuous research and development efforts have led to the introduction of innovative products such as long-acting reversible contraceptives (LARCs) and non-invasive methods. These advancements have not only increased the efficacy of birth control methods but also reduced side effects, thereby improving user satisfaction and adherence. Furthermore, the development of male contraceptive solutions is also gaining momentum, indicating a shift towards shared responsibility in family planning. These technological innovations are anticipated to attract a broader consumer base, thereby driving market growth over the forecast period.

The growing prevalence of unintended pregnancies, which often result in various socio-economic challenges, is a major factor bolstering the demand for birth control products. Unintended pregnancies can lead to increased healthcare costs, higher rates of maternal and infant morbidity and mortality, and can place a financial and emotional burden on families. Consequently, there is an urgent need to address this issue globally, which is being tackled through the increased availability and accessibility of contraceptive products. This scenario is supported by favorable government policies and funding for family planning programs, further facilitating market expansion. Additionally, the increasing participation of private players in offering affordable contraceptive options is also aiding in mitigating the challenges posed by unintended pregnancies, thereby supporting market growth.

Birth Control Pills remain a cornerstone in the realm of contraceptive options, offering a reliable and convenient method for many individuals. These pills are favored for their effectiveness in preventing pregnancy when taken consistently and correctly. Over the years, the formulations of birth control pills have evolved, with lower doses of hormones aimed at reducing side effects while maintaining efficacy. This evolution has contributed to their sustained popularity among users who seek a balance between convenience and control over their reproductive health. The availability of various formulations allows healthcare providers to tailor prescriptions to meet individual health needs, further enhancing their appeal. As awareness and education about reproductive health continue to grow, birth control pills are expected to maintain their significant role in the contraceptive market.

Regionally, the birth control products market exhibits significant variation in growth rates and market dynamics. North America and Europe currently dominate the market due to high awareness levels, comprehensive healthcare systems, and favorable government policies supporting contraceptive use. However, the Asia

In the period 2023/24, 58 percent of women in England aged 16 and 17 years who were in contact with sexual health services were using user dependent contraceptives, compared to 42 percent who were using long acting reversible contraceptives (LARCs). It is visible that younger age groups were more likely to use user-dependent contraceptives compared to older age groups. Contact with sexual health services In total, over 1.9 million women in England contacted NHS sexual and reproductive health services for contraceptive reasons in the period 2020/21. The age group with the highest number of women contacting the service was those aged 25-34 years. Types of contraception used Across the whole United Kingdom in 2018, the birth control pill was the most common method of contraception for women aged between 15 and 49 years, with 28 percent using it as their main method. Across Europe, the UK had the seventh highest share of women in the country using the pill as their main method of contraception, with Czechia having the highest share at 54 percent of women in the country using the pill.

The global contraceptives drugs market is a significant and dynamic sector, projected to experience substantial growth between 2025 and 2033. While precise figures for market size and CAGR are unavailable, a reasonable estimation, based on industry reports and the presence of major pharmaceutical players like Bayer, Pfizer, and Johnson & Johnson, suggests a market valued in the tens of billions of USD in 2025. Growth is fueled by several key drivers, including increasing awareness of family planning and reproductive health, rising female participation in the workforce, and government initiatives promoting access to contraceptives in developing countries. Furthermore, advancements in contraceptive technology, such as the development of long-acting reversible contraceptives (LARCs) like IUDs and implants, are contributing to market expansion. However, factors such as cultural and religious beliefs, limited access to healthcare in certain regions, and concerns about potential side effects of specific contraceptives represent key restraints. The market is segmented based on contraceptive type (oral contraceptives, injectables, implants, IUDs, etc.), distribution channels (pharmacies, hospitals, clinics), and geography. Competition is intense among established pharmaceutical giants and emerging players, driving innovation and price competition. The competitive landscape is characterized by a mix of multinational corporations with extensive research and development capabilities and regional players catering to specific market needs. The forecast period (2025-2033) is expected to witness continued growth, driven by factors such as increasing urbanization, rising disposable incomes in developing economies, and ongoing efforts to improve global reproductive health outcomes. Regional variations will likely persist, with developed markets exhibiting relatively stable growth while developing markets experiencing more significant expansion. The market's future depends on continuous innovation in contraceptive methods, improved access to healthcare services, and sustained governmental support for family planning programs worldwide. This necessitates strategic planning and investment by companies operating in this sector to effectively capitalize on opportunities and mitigate potential challenges.

The Birth Control Pills market represents a dynamic segment of the global contraceptive landscape, primarily used to prevent pregnancy and regulate hormonal cycles. With a growing emphasis on reproductive health, these oral contraceptives have become a cornerstone for many individuals seeking safe and effective birt

The birth control patch market is experiencing robust growth, driven by increasing awareness of convenient and effective contraception options among women. While precise market size figures for 2025 are not provided, let's assume a conservative estimate of $1.5 billion based on similar markets and reported CAGRs in the pharmaceutical sector. Considering a plausible CAGR of 7% for the forecast period (2025-2033), the market is projected to reach approximately $2.8 billion by 2033. This growth is fueled by several key factors including rising disposable incomes, particularly in developing economies, increased access to healthcare, and a shift towards non-invasive contraceptive methods. The preference for discreet and user-friendly options like the patch, compared to daily pills or injections, significantly contributes to market expansion. Furthermore, the growing acceptance of hormonal contraceptives, alongside targeted marketing campaigns and physician recommendations, are instrumental in driving demand. The market segmentation reveals a strong preference for seven-day replacement patches due to their enhanced convenience and efficacy, particularly within the online sales channel, reflecting changing consumer behavior. However, potential restraints like concerns about side effects and the slightly higher cost compared to oral contraceptives need to be carefully considered. The market is geographically diversified, with North America currently holding a substantial share due to high healthcare expenditure and established healthcare infrastructure. However, rapid growth is anticipated in Asia-Pacific regions like India and China, driven by rising female literacy rates, increased urbanization, and improved access to healthcare services. Competitive dynamics are shaped by established pharmaceutical giants alongside emerging players, resulting in ongoing innovation in patch formulations and delivery systems. Further market expansion will depend on addressing regulatory hurdles, investing in research and development for improved formulations, and continuing to educate consumers about the benefits and safety of the birth control patch. Future opportunities lie in developing personalized patch formulations catering to individual needs and preferences, as well as expanding distribution channels for improved accessibility.

Philippines PH: Contraceptive Prevalence: Modern Methods: % of Women Aged 15-49 data was reported at 37.600 % in 2013. This records an increase from the previous number of 36.800 % for 2011. Philippines PH: Contraceptive Prevalence: Modern Methods: % of Women Aged 15-49 data is updated yearly, averaging 33.100 % from Dec 1978 (Median) to 2013, with 17 observations. The data reached an all-time high of 37.600 % in 2013 and a record low of 16.200 % in 1978. Philippines PH: Contraceptive Prevalence: Modern Methods: % of Women Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Philippines – Table PH.World Bank.WDI: Health Statistics. Contraceptive prevalence rate is the percentage of women who are practicing, or whose sexual partners are practicing, at least one modern method of contraception. It is usually measured for women ages 15-49 who are married or in union. Modern methods of contraception include female and male sterilization, oral hormonal pills, the intra-uterine device (IUD), the male condom, injectables, the implant (including Norplant), vaginal barrier methods, the female condom and emergency contraception.; ; Household surveys, including Demographic and Health Surveys and Multiple Indicator Cluster Surveys. Largely compiled by United Nations Population Division.; Weighted average;

United States US: Unmet Need for Contraception: % of Married Women Aged 15-49 data was reported at 9.000 % in 2014. This records an increase from the previous number of 8.000 % for 2010. United States US: Unmet Need for Contraception: % of Married Women Aged 15-49 data is updated yearly, averaging 6.000 % from Dec 1988 (Median) to 2014, with 7 observations. The data reached an all-time high of 9.000 % in 2014 and a record low of 4.000 % in 1988. United States US: Unmet Need for Contraception: % of Married Women Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Unmet need for contraception is the percentage of fertile, married women of reproductive age who do not want to become pregnant and are not using contraception.; ; Household surveys, including Demographic and Health Surveys and Multiple Indicator Cluster Surveys. Largely compiled by United Nations Population Division.; Weighted Average; Unmet need for contraception measures the capacity women have in achieving their desired family size and birth spacing. Many couples in developing countries want to limit or postpone childbearing but are not using effective contraception. These couples have an unmet need for contraception. Common reasons are lack of knowledge about contraceptive methods and concerns about possible side effects.

This dataset includes the following variables: number of contraceptive implants; intrauterine contraceptives (IUCs); Essure procedures and tubal ligation services delivered by providers and the number of female clients receiving these services; number of vasectomies delivered by providers and number received by male clients.